ASPP and iASPP: Implication in cancer development and progression

Cellular and Molecular Biology

Volumn 61, Issue 6, 2015, Pages 2-8

  Li, Y ^a   Ahmad, A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; ASPP1; ASPP2; IASPP; P53

Indexed keywords

APOPTOSIS STIMULATING PROTEIN OF P53; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS STIMULATING PROTEIN OF P53; MICRORNA 124; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; DNA DAMAGE; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; NEOPLASMS; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; NEOPLASMS; NF-KAPPA B;

EID: 84962205018     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.6.2     Document Type: Article

References (84)

1. Vousden, K. H. and Lu, X., Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2: 594-604, doi:10.1038/nrc864
2. Liu, Z. J., Lu, X. and Zhong, S., ASPP--Apoptotic specific regulator of p53. Biochim. Biophys. Acta 2005, 1756: 77-80, doi:10.1016/j.bbcan.2005.08.002
3. Slee, E. A. and Lu, X., The ASPP family: deciding between life and death after DNA damage. Toxicol. Lett. 2003, 139: 81-87
4. Sullivan, A. and Lu, X., ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 2007, 96: 196-200, doi:10.1038/sj.bjc.6603525
5. Vives, V., Slee, E. A. and Lu, X., ASPP2: a gene that controls life and death in vivo. Cell Cycle 2006, 5: 2187-2190
6. Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del, S. G., Syed, N., Smith, P., Gasco, M., Crook, T. and Lu, X., iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 2006, 38: 1133-1141, doi:10.1038/ng1879
7. Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J. K., Zhong, S., Campargue, I., Naumovski, L., Crook, T. and Lu, X., ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 2001, 8: 781-794, doi:S1097-2765(01)00367-7
8. Naumovski, L. and Cleary, M. L., The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol. Cell Biol. 1996, 16: 3884-3892
9. Yang, J. P., Hori, M., Takahashi, N., Kawabe, T., Kato, H. and Okamoto, T., NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999, 18: 5177-5186, doi:10.1038/sj.onc.1202904
10. Bergamaschi, D., Samuels, Y., O'Neil, N. J., Trigiante, G., Crook, T., Hsieh, J. K., O'Connor, D. J., Zhong, S., Campargue, I., Tomlinson, M. L., Kuwabara, P. E. and Lu, X., iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 2003, 33: 162-167, doi:10.1038/ng1070
11. Slee, E. A., Gillotin, S., Bergamaschi, D., Royer, C., Llanos, S., Ali, S., Jin, B., Trigiante, G. and Lu, X., The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 2004, 23: 9007-9016, doi:10.1038/sj.onc.1208088
12. Zhang, X., Diao, S., Rao, Q., Xing, H., Liu, H., Liao, X., Wang, M. and Wang, J., Identification of a novel isoform of iASPP and its interaction with p53. J. Mol. Biol. 2007, 368: 1162-1171, doi:10.1016/j.jmb.2007.03.001
13. Notari, M., Hu, Y., Koch, S., Lu, M., Ratnayaka, I., Zhong, S., Baer, C., Pagotto, A., Goldin, R., Salter, V., Candi, E., Melino, G. and Lu, X., Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc. Natl. Acad. Sci. U. S. A 2011, 108: 16645-16650, doi:10.1073/pnas.1102292108
14. Trigiante, G. and Lu, X., ASPP [corrected] and cancer. Nat. Rev. Cancer 2006, 6: 217-226, doi:10.1038/nrc1818
15. Agirre, X., Roman-Gomez, J., Jimenez-Velasco, A., Garate, L., Montiel-Duarte, C., Navarro, G., Vazquez, I., Zalacain, M., Calasanz, M. J., Heiniger, A., Torres, A., Minna, J. D. and Prosper, F., ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 2006, 25: 1862-1870, doi:10.1038/sj.onc.1209236
16. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Prosper, F., Heiniger, A. and Torres, A., Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Oncol. 2005, 23: 7043-7049, doi:10.1200/JCO.2005.01.4944
17. Liu, Z. J., Lu, X., Zhang, Y., Zhong, S., Gu, S. Z., Zhang, X. B., Yang, X. and Xin, H. M., Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 2005, 579: 1587-1590, doi:10.1016/j.febslet.2005.01.069
18. Zhao, J., Wu, G., Bu, F., Lu, B., Liang, A., Cao, L., Tong, X., Lu, X., Wu, M. and Guo, Y., Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 2010, 51: 142-153, doi:10.1002/hep.23247
19. Chen, D., Padiernos, E., Ding, F., Lossos, I. S. and Lopez, C. D., Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death. Differ. 2005, 12: 358-368, doi:10.1038/sj.cdd.4401536
20. Fogal, V., Kartasheva, N. N., Trigiante, G., Llanos, S., Yap, D., Vousden, K. H. and Lu, X., ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death. Differ. 2005, 12: 369-376, doi:10.1038/sj.cdd.4401562
21. Hershko, T., Chaussepied, M., Oren, M. and Ginsberg, D., Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death. Differ. 2005, 12: 377-383, doi:10.1038/sj.cdd.4401575
22. Stanelle, J., Stiewe, T., Theseling, C. C., Peter, M. and Putzer, B. M., Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 2002, 30: 1859-1867
23. Li, Z., Stanelle, J., Leurs, C., Hanenberg, H. and Putzer, B. M., Selection of novel mediators of E2F1-induced apoptosis through retroviral expression of an antisense cDNA library. Nucleic Acids Res. 2005, 33: 2813-2821, doi:10.1093/nar/gki581
24. Zhu, Z., Ramos, J., Kampa, K., Adimoolam, S., Sirisawad, M., Yu, Z., Chen, D., Naumovski, L. and Lopez, C. D., Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. J. Biol. Chem. 2005, 280: 34473-34480, doi:10.1074/jbc.M503736200
25. Gorina, S. and Pavletich, N. P., Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996, 274: 1001-1005
26. Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R. and Fields, S., Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. U. S. A 1994, 91: 6098-6102
27. Bergamaschi, D., Samuels, Y., Jin, B., Duraisingham, S., Crook, T. and Lu, X., ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell Biol. 2004, 24: 1341-1350
28. Takahashi, N., Kobayashi, S., Kajino, S., Imai, K., Tomoda, K., Shimizu, S. and Okamoto, T., Inhibition of the 53BP2S-mediated apoptosis by nuclear factor kappaB and Bcl-2 family proteins. Genes Cells 2005, 10: 803-811, doi:10.1111/j.1365-2443.2005.00878.x
29. Zhang, Y., Wang, Y., Wei, Y., Ma, J., Peng, J., Wumaier, R., Shen, S., Zhang, P. and Yu, L., The tumor suppressor proteins ASPP1 and ASPP2 interact with C-Nap1 and regulate centrosome linker reassembly. Biochem. Biophys. Res. Commun. 2015, 458: 494-500, doi:10.1016/j.bbrc.2015.01.136
30. Godin-Heymann, N., Wang, Y., Slee, E. and Lu, X., Phosphorylation of ASPP2 by RAS/MAPK pathway is critical for its full pro-apoptotic function. PLoS. One. 2013, 8: e82022, doi:10.1371/journal.pone.0082022
31. Wang, Y., Godin-Heymann, N., Dan, W., X, Bergamaschi, D., Llanos, S. and Lu, X., ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death. Differ. 2013, 20: 525-534, doi:10.1038/cdd.2013.3
32. Janke, K., Brockmeier, U., Kuhlmann, K., Eisenacher, M., Nolde, J., Meyer, H. E., Mairbaurl, H. and Metzen, E., Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2). J. Cell Sci. 2013, 126: 2629-2640, doi:10.1242/jcs.117564
33. Skene-Arnold, T. D., Luu, H. A., Uhrig, R. G., De, W., V, Nimick, M., Maynes, J., Fong, A., James, M. N., Trinkle-Mulcahy, L., Moorhead, G. B. and Holmes, C. F., Molecular mechanisms underlying the interaction of protein phosphatase-1c with ASPP proteins. Biochem. J. 2013, 449: 649-659, doi:10.1042/BJ20120506
34. Llanos, S., Royer, C., Lu, M., Bergamaschi, D., Lee, W. H. and Lu, X., Inhibitory member of the apoptosis-stimulating proteins of the p53 family (iASPP) interacts with protein phosphatase 1 via a noncanonical binding motif. J. Biol. Chem. 2011, 286: 43039-43044, doi:10.1074/jbc.M111.270751
35. Gillotin, S. and Lu, X., The ASPP proteins complex and cooperate with p300 to modulate the transcriptional activity of p53. FEBS Lett. 2011, 585: 1778-1782, doi:10.1016/j.febslet.2011.04.012
36. Patel, S., George, R., Autore, F., Fraternali, F., Ladbury, J. E. and Nikolova, P. V., Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res. 2008, 36: 5139-5151, doi:10.1093/nar/gkn490
37. Robinson, R. A., Lu, X., Jones, E. Y. and Siebold, C., Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure. 2008, 16: 259-268, doi:10.1016/j.str.2007.11.012
38. Ahn, J., Byeon, I. J., Byeon, C. H. and Gronenborn, A. M., Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J. Biol. Chem. 2009, 284: 13812-13822, doi:10.1074/jbc.M808821200
39. Mantovani, F., Tocco, F., Girardini, J., Smith, P., Gasco, M., Lu, X., Crook, T. and Del, S. G., The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat. Struct. Mol. Biol. 2007, 14: 912-920, doi:10.1038/nsmb1306
40. Vigneron, A. M., Ludwig, R. L. and Vousden, K. H., Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 2010, 24: 2430-2439, doi:10.1101/gad.1954310
41. Liu, Z. J., Zhang, Y., Zhang, X. B. and Yang, X., Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 2004, 18: 880, doi:10.1038/sj.leu.2403300
42. Mak, V. C., Lee, L., Siu, M. K., Wong, O. G., Lu, X., Ngan, H. Y., Wong, E. S. and Cheung, A. N., Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis 2013, 34: 2170-2177, doi:10.1093/carcin/bgt161
43. Zhang, X., Wang, M., Zhou, C., Chen, S. and Wang, J., The expression of iASPP in acute leukemias. Leuk. Res. 2005, 29: 179-183, doi:10.1016/j.leukres.2004.07.001
44. Jia, Y., Peng, L., Rao, Q., Xing, H., Huai, L., Yu, P., Chen, Y., Wang, C., Wang, M., Mi, Y. and Wang, J., Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation. FASEB J. 2014, 28: 2816-2827, doi:10.1096/fj.13-244632
45. Li, S., Shi, G., Yuan, H., Zhou, T., Zhang, Q., Zhu, H. and Wang, X., Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP. Oncol. Rep. 2012, 28: 133-140, doi:10.3892/or.2012.1778
46. Chen, J., Xie, F., Zhang, L. and Jiang, W. G., iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC. Cancer 2010, 10: 694, doi:10.1186/1471-2407-10-694
47. Zhang, B., Xiao, H. J., Chen, J., Tao, X. and Cai, L. H., Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53-deficient prostate cancer cells. Prostate Cancer Prostatic. Dis. 2011, 14: 219-224, doi:10.1038/pcan.2011.25
48. Liu, T., Li, L., Yang, W., Jia, H., Xu, M., Bi, J., Li, Z., Liu, X., Li, Z., Jing, H. and Kong, C., iASPP is important for bladder cancer cell proliferation. Oncol. Res. 2011, 19: 125-130
49. Wang, L. L., Xu, Z., Peng, Y., Li, L. C. and Wu, X. L., Downregulation of inhibitor of apoptosisstimulating protein of p53 inhibits proliferation and promotes apoptosis of gastric cancer cells. Mol. Med. Rep. 2015, doi:10.3892/mmr.2015.3587
50. Lin, B. L., Xie, D. Y., Xie, S. B., Xie, J. Q., Zhang, X. H., Zhang, Y. F. and Gao, Z. L., Down-regulation of iASPP in human hepatocellular carcinoma cells inhibits cell proliferation and tumor growth. Neoplasma 2011, 58: 205-210
51. Morris, E. V., Cerundolo, L., Lu, M., Verrill, C., Fritzsche, F., White, M. J., Thalmann, G. N., ten Donkelaar, C. S., Ratnayaka, I., Salter, V., Hamdy, F. C., Lu, X. and Bryant, R. J., Nuclear iASPP may facilitate prostate cancer progression. Cell Death. Dis. 2014, 5: e1492, doi:10.1038/cddis.2014.442
52. Chen, Y., Yan, W., He, S., Chen, J., Chen, D., Zhang, Z., Liu, Z., Ding, X. and Wang, A., In vitro effect of iASPP on cell growth of oral tongue squamous cell carcinoma. Chin J. Cancer Res. 2014, 26: 382-390, doi:10.3978/j.issn.1000-9604.2014.07.05
53. Kim, J. W., Roh, J. L., Park, Y., Cho, K. J., Choi, S. H., Nam, S. Y. and Kim, S. Y., Cytoplasmic iASPP expression as a novel prognostic indicator in oral cavity squamous cell carcinoma. Ann. Surg. Oncol. 2015, 22: 662-669, doi:10.1245/s10434-014-4003-0
54. Cao, L., Huang, Q., He, J., Lu, J. and Xiong, Y., Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2013, 352: 361-369, doi:10.1007/s00441-013-1569-y
55. Liu, Z., Zhang, X., Huang, D., Liu, Y., Zhang, X., Liu, L., Li, G., Dai, Y., Tan, H., Xiao, J. and Tian, Y., Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Med. Oncol. 2012, 29: 3381-3388, doi:10.1007/s12032-012-0306-9
56. Jiang, L., Siu, M. K., Wong, O. G., Tam, K. F., Lu, X., Lam, E. W., Ngan, H. Y., Le, X. F., Wong, E. S., Monteiro, L. J., Chan, H. Y. and Cheung, A. N., iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin. Cancer Res. 2011, 17: 6924-6933, doi:10.1158/1078-0432.CCR-11-0588
57. Lu, B., Guo, H., Zhao, J., Wang, C., Wu, G., Pang, M., Tong, X., Bu, F., Liang, A., Hou, S., Fan, X., Dai, J., Wang, H. and Guo, Y., Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-kappaB activation, in hepatocellular carcinoma. Gastroenterology 2010, 139: 2183-2194, doi:10.1053/j.gastro.2010.06.049
58. Lu, M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I., Sullivan, A., Brown, N. R., Endicott, J., Knapp, S., Kessler, B. M., Middleton, M. R., Siebold, C., Jones, E. Y., Sviderskaya, E. V., Cebon, J., John, T., Caballero, O. L., Goding, C. R. and Lu, X., Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013, 23: 618-633, doi:10.1016/j.ccr.2013.03.013
59. Mori, T., Okamoto, H., Takahashi, N., Ueda, R. and Okamoto, T., Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett. 2000, 465: 124-128, doi:S0014-5793(99)01726-3
60. Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rudiger, S. and Fersht, A. R., A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. U. S. A 2002, 99: 937-942, doi:10.1073/pnas.241629998
61. Bell, H. S., Dufes, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., Schatzlein, A. G., Vousden, K. H. and Ryan, K. M., A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J. Clin. Invest 2007, 117: 1008-1018, doi:10.1172/JCI28920
62. Bell, H. S. and Ryan, K. M., iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res. 2008, 68: 4959-4962, doi:10.1158/0008-5472.CAN-08-0182
63. Qiu, S., Cai, Y., Gao, X., Gu, S. Z. and Liu, Z. J., A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53. Cancer Lett. 2015, 356: 910-917, doi:10.1016/j.canlet.2014.10.044
64. Liu, Z. J., Cai, Y., Hou, L., Gao, X., Xin, H. M., Lu, X., Zhong, S., Gu, S. Z. and Chen, J., Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest 2008, 26: 878-882, doi:10.1080/07357900801965042
65. Liu, H., Wang, M., Diao, S., Rao, Q., Zhang, X., Xing, H. and Wang, J., siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk. Res. 2009, 33: 1243-1248, doi:10.1016/j.leukres.2009.02.016
66. Chen, J., Xiao, H., Huang, Z., Hu, Z., Qi, T., Zhang, B., Tao, X. and Liu, S. H., MicroRNA124 regulate cell growth of prostate cancer cells by targeting iASPP. Int. J. Clin. Exp. Pathol. 2014, 7: 2283-2290
67. Liu, K., Zhao, H., Yao, H., Lei, S., Lei, Z., Li, T. and Qi, H., MicroRNA-124 regulates the proliferation of colorectal cancer cells by targeting iASPP. Biomed. Res. Int. 2013, 2013: 867537, doi:10.1155/2013/867537
68. Zhao, W. H., Wu, S. Q. and Zhang, Y. D., Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. Int. J. Mol. Med. 2013, 32: 101-107, doi:10.3892/ijmm.2013.1365
69. Liu, X., Li, F., Zhao, S., Luo, Y., Kang, J., Zhao, H., Yan, F., Li, S. and Ji, X., MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke 2013, 44: 1973-1980, doi:10.1161/STROKEAHA.111.000613
70. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G., Masucci, M., Pramanik, A. and Selivanova, G., Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10: 1321-1328, doi:10.1038/nm1146
71. Wang, Y., Xu, S. L., Wu, Y. Z., Zhao, M. S., Xu, W. J., Yang, H. Y. and Li, Y. X., Simvastatin induces caspase-dependent apoptosis and activates P53 in OCM-1 cells. Exp. Eye Res. 2013, 113: 128-134, doi:10.1016/j.exer.2013.05.013
72. Shi, Y., Yang, S., Troup, S., Lu, X., Callaghan, S., Park, D. S., Xing, Y. and Yang, X., Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol. Rep. 2011, 25: 1713-1719, doi:10.3892/or.2011.1248
73. Masood, N., Qureshi, M. Z. and Yasmin, A., Association of NOTCH with different microRNAs in head and neck cancer. Cell. Mol. Biol. 2015, 61(6): 9-16.
74. Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolkenhauerand, O. and Schmitz, U., The role of microRNAs in the resistance to colorectal cancer treatments. Cell. Mol. Biol. 2015, 61(6): 17-23.
75. Wang, Z., Chen, J. and Capobianco, A. J., The Notch signaling pathway in esophageal adenocarcinoma. Cell. Mol. Biol. 201561, (6): 24-32.
76. Limami, Y., Pinon, A., Riaz, A. and Simon, A., TRAIL and targeting cancer cells: between promises and obstacles. Cell. Mol. Biol. 201561, (6): 33-38.
77. Silva Galbiatti-Dias, A. L., Pavarino, É. C., Kawasaki-Oyama, R. S., Maniglia, J. V., Maniglia, E. J. V. and Goloni Bertollo, E. M., Cancer stem cells in head and neck cancer: A Mini Review. Cell. Mol. Biol. 2015, 61(6): 39-43.
78. Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Casorelli, A., Domenici, L., Imperiale, L., Ruscito, I., Abdul Halim, T., Palaia, I., Di Donato, V., Pecorini, F., Monti, M., Muzii, L. and Panici, P. B., PARP inhibition: A promising therapeutic target in ovarian cancer. Cell. Mol. Biol. 201561, (6): 44-61.
79. Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M. S., Nogueira, D. R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A. A. and Ismail, M., Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell. Mol. Biol. 2015, 61(6): 62-68.
80. Hsu, Y-C., Hsieh, Y-H., Liao, C-C., Chong, L-W., Lee, C-Y., Yu, Y-L. and Chou, R-H., Targeting post-translational modifications of histones for cancer therapy. Cell. Mol. Biol. 2015, 61(6): 69-84.
81. Chong, L-W., Chou, R-H., Liao, C-C., Lee, T-F., Lin, Y., Yang, K-C. and Hsu, Y-C. Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells. Cell. Mol. Biol. 201561, (6): 85-91.
82. Smina, T. P., Mohan, A., Ayyappa, K. A., Sethuraman, S. and Krishnan, U. M., Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins. Cell. Mol. Biol. 2015, 61(6): 92-99.
83. Ahmadi, M., Jafari, R., Marashi, S. A. and Farazmand, A., Indirect role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach. Cell. Mol. Biol. 2015, 61(6): 100-107.
84. Zahoor, A., Mansoor, Q., Farooqi, A. A., Fayyaz, S., Naz, G. and Ismail, M., Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population. Cell. Mol. Biol. 2015, 61(6): 108-112.